Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Mass Spectrometry Technology Maps Chemicals as They Migrate Into Skin

By BiotechDaily International staff writers
Posted on 14 May 2014
Print article
A mass spectrometry technique gaining acceptance for medical applications such as imaging tumor surfaces can also be used to analyze the migration of small-molecule compounds applied to the skin. Because skin is such a complicated organ, the technology could be a helpful for developing transdermal drugs.

The study’s findings were published April 28, 2014, in the Journal of the American Chemical Society. Stanford University (Stanford, CA, USA) chemistry Profs. Richard N. Zare and Justin Du Bois, postdoc Livia S. Eberlin, graduate student John V. Mulcahy, and colleagues revealed that desorption electrospray ionization-mass spectrometry (DESI-MS) imaging has many advantages over other approaches that require complicated preparation of skin samples.

Moreover, DESI-MS imaging can be performed under ambient settings, instead of in a vacuum condition, as other MS methods require. Furthermore, test compounds do not have to be radioactively labeled or tagged with unwieldy dye molecules that could affect the compounds’ normal migration through skin. “That’s why this method is very appealing,” said Mark R. Prausnitz, a chemical and biomolecular engineering professor who heads the Laboratory for Drug Delivery at Georgia Institute of Technology (Atlanta, GA, USA).

DESI-MS was developed 10 years ago and involves spraying charged solvent droplets at a surface. Backsplash droplets containing dissolved molecules are then captured and examined using a mass spectrometer. The technology has been used for medical applications such as imaging drugs in tissue samples.

The Stanford scientists chose a number of small molecules that change sodium channels in skin cells, including lidocaine and a shellfish toxin. They applied them to the surface of skin samples and were able to track the compounds’ migration to a depth of 1.2 mm.

Such studies of drug migration are required to enlarge the limited selection of transdermal drugs, according to Prof. Prausnitz. Only approximately 30 agents, such as nicotine, have transdermal versions. The drugs must be small, lipophilic, and effective at a low dose. With this newly adapted tool, however, scientists could more readily study methods to enhance skin permeation, Prof. Prausnitz reported. “We’re very interested in the pathway--which part of the skin did the drug go through?”

Related Links:

Stanford University



Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.